Abstract:Paradoxically, tumor development and progression can be inhibited and promoted by the immune system. After three stages of immune editing, namely, elimination, homeostasis and escape, tumor cells are no longer restricted by immune surveillance and thus develop into clinical tumors. The mechanisms of immune escape include abnormalities in antitumor-associated immune cells, selection for immune resistance to tumor cells, impaired transport of T cells, and the formation of an immunosuppressive tumor microenvironment. A population of distinct immature myeloid cells, myeloid-derived suppressor cells (MDSCs), mediate immune escape primarily by exerting immunosuppressive effects and participating in the constitution of an immunosuppressive microtumor environment. Clinical trials have found that the levels of MDSCs in the peripheral blood of cancer patients are strongly correlated with tumor stage, metastasis and prognosis. Moreover, animal experiments have confirmed that elimination of MDSCs inhibits tumor growth and metastasis to some extent. Therefore, MDSCs may become the target of immunotherapy for many cancers, and eliminating MDSCs can help improve the response rate to cancer treatment and patient survival. However, a clear definition of MDSCs and the specific mechanism involved in immune escape are lacking. In this paper, we review the role of the MDSCs population in tumor development and the mechanisms involved in immune escape in different tumor contexts. In addition, we discuss the use of these cells as targets for tumor immunotherapy. This review not only contributes to a systematic and comprehensive understanding of the essential role of MDSCs in immune system reactions against tumors but also provides information to guide the development of cancer therapies targeting MDSCs.

Secreted microRNAs from tumor cells can suppress immune function.

Tumor-secreted microRNAs act as intercellular communication mediators to manipulate the host immune system

MicroRNAs: immune modulators in cancer immunotherapy

Tumor-secreted Mir-214 Induces Regulatory T Cells: a Major Link Between Immune Evasion and Tumor Growth

Suppressive Myeloid Cells Shape the Tumor Immune Microenvironment

Regulation of tumor immunity by microRNAs

PD-L1+ Exosomes from Bone Marrow-Derived Cells of Tumor-Bearing Mice Inhibit Antitumor Immunity

Tumor Immune Microenvironment and Its Related miRNAs in Tumor Progression

Biological Functions and Molecular Mechanisms of MiR-608 in Cancer

TGF-β-Regulated MicroRNAs and Their Function in Cancer Biology.

Exosome-Mediated Immunosuppression in Tumor Microenvironments

Interleukin 33 in Tumor Microenvironment is Crucial for the Accumulation and Function of Myeloid-Derived Suppressor Cells

The Role of miRNA in Tumor Immune Escape and miRNA-Based Therapeutic Strategies

Immune modulatory microRNAs in tumors, their clinical relevance in diagnosis and therapy

Tumor-derived exosomes, microRNAs, and cancer immune suppression

MiRNAs in Cancer Therapy: Focusing on Their Bi-Directional Roles

Cancer-derived Circulating MicroRNAs Promote Tumor Angiogenesis by Entering Dendritic Cells to Degrade Highly Complementary MicroRNAs.

Cancer-secreted exosomal miR-1468-5p promotes tumor immune escape via the immunosuppressive reprogramming of lymphatic vessels

Myeloid-derived suppressor cells in cancer: therapeutic targets to overcome tumor immune evasion

Tumor evolution selectively inactivates the core microRNA machinery for immune evasion

MicroRNAs Involved in Anti-Tumour Immunity